DBV Technologies (NASDAQ:DBVT) Posts Earnings Results, Misses Estimates By $1.27 EPS

Key Points

• DBV Technologies reported a quarterly loss of ($1.55) EPS, significantly missing analysts' estimates of ($0.28) by ($1.27).
• The company has a negative net margin of 3,249.99% and a return on equity of -278.24% as it continues its research and development of immunotherapy products.
• Analysts have mixed ratings on DBV Technologies, with two selling, three buying, and one strong buy recommendation, resulting in a consensus rating of "Moderate Buy" with an average target price of $14.75.

DBV Technologies (NASDAQ:DBVT - Get Free Report) issued its quarterly earnings data on Tuesday. The company reported ($1.55) EPS for the quarter, missing analysts' consensus estimates of ($0.28) by ($1.27), Zacks reports. DBV Technologies had a negative net margin of 3,249.99% and a negative return on equity of 278.24%.

DBV Technologies Stock Performance

DBVT stock traded up $0.07 during midday trading on Tuesday, hitting $9.80. 174,117 shares of the company's stock were exchanged, compared to its average volume of 223,529. The stock's fifty day moving average price is $9.48 and its 200-day moving average price is $7.33. The company has a market cap of $268.42 million, a PE ratio of -1.99 and a beta of -0.59. DBV Technologies has a one year low of $2.20 and a one year high of $12.78.

Analyst Upgrades and Downgrades

DBVT has been the subject of several recent analyst reports. Wall Street Zen downgraded DBV Technologies from a "hold" rating to a "sell" rating in a research note on Friday, July 18th. HC Wainwright increased their target price on DBV Technologies from $7.00 to $16.00 and gave the company a "buy" rating in a research note on Monday, May 5th. JMP Securities restated a "market outperform" rating and set a $21.00 target price on shares of DBV Technologies in a research note on Thursday, June 26th. Citigroup reiterated an "outperform" rating on shares of DBV Technologies in a research report on Tuesday, May 27th. Finally, The Goldman Sachs Group upgraded DBV Technologies to a "sell" rating and set a $7.25 price objective for the company in a research report on Thursday, May 29th. Two investment analysts have rated the stock with a sell rating, three have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, DBV Technologies presently has a consensus rating of "Moderate Buy" and an average target price of $14.75.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.